A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT01326000. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Open-label Phase II Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With KRAS Wild-type or Mutant Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT01326000
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 169 participants
Conditions and interventions
Conditions
Interventions
- FOLFIRI Drug
- RO5083945 Drug
- cetuximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011
- Primary completion
- Nov 30, 2013
- Completion
- Nov 30, 2013
- Last update posted
- Nov 16, 2022
2011 – 2013
United States locations
- U.S. sites
- 16
- U.S. states
- 6
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Encinitas | California | 92024 | — |
| Not listed | Highland | California | 92346 | — |
| Not listed | La Jolla | California | 92037 | — |
| Not listed | La Verne | California | 91750 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | Harvey | Illinois | 60426 | — |
| Not listed | Skokie | Illinois | 60076 | — |
| Not listed | Skokie | Illinois | 60077 | — |
| Not listed | Charlotte | North Carolina | 28204 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Sayre | Pennsylvania | 18840 | — |
| Not listed | Greenville | South Carolina | 29615 | — |
| Not listed | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01326000, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2022 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01326000 live on ClinicalTrials.gov.